Keywords: atripla, approved, canada, hiv-1, drugmakers, bristol-myers, squibb
Atripla approved in Canada for HIV-1
Article | 22 October 2007
US drugmakers Bristol-Myers Squibb and Gilead Sciences says Health Canada has approved Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
